Opendata, web and dolomites

MedicalPhant SIGNED

An advanced 3D simulator to generate 3D-personalized tissue and organ models for diagnosis, planning and pre-treatment of medical vascular interventions

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 MedicalPhant project word cloud

Explore the words cloud of the MedicalPhant project. It provides you a very rough idea of what is the project "MedicalPhant" about.

replicate    associations    capacity    ones    3m    mri    planning    charge    company    stakeholders    safety    business    mark    estimation    plan    hospitals    emerged    eco    amount    certification    interventions    6    public    diagnostic    licensing    market    physical    model    commercialized    pathology    situations    models    carry    device    mechanical    3d    treatment    personalized    consists    penetration    obtain    combination    death    trials    organ    environment    clinical    flow    diseases    external    medical    projected    fda    validated    simulator    private    prototype    simulating    initial    patients    intervention    cardiovascular    provides    leaders    innovative    ce    vasculature    surgery    commercialize    errors    trl6    opinion    specialized    identical    improves    roi    internal    certificating    innovation    valida    diagnosis    industrial    patient    cat    medicalphant    plus    acute    cumulative    universities    cash    globally    printing   

Project "MedicalPhant" data sheet

The following table provides information about the project.

Coordinator
VALIDA INNOVATION SOCIEDAD LIMITADA 

Organization address
address: CALLE HERNAN CORTES, NUM 24 PLANTA 1 PUERTA 1
city: VALENCIA
postcode: 46004
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Spain [ES]
 Project website https://www.validainnovation.com/medicalphant/
 Total cost 71˙429 €
 EC max contribution 50˙000 € (70%)
 Programme 1. H2020-EU.3. (PRIORITY 'Societal challenges)
2. H2020-EU.2.3. (INDUSTRIAL LEADERSHIP - Innovation In SMEs)
3. H2020-EU.2.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies)
 Code Call H2020-SMEInst-2018-2020-1
 Funding Scheme SME-1
 Starting year 2018
 Duration (year-month-day) from 2018-06-01   to  2018-09-30

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    VALIDA INNOVATION SOCIEDAD LIMITADA ES (VALENCIA) coordinator 50˙000.00

Map

 Project objective

VALIDA INNOVATION S.L. emerged with the goal of developing a new 3D simulator that improves the diagnosis, planning and pre-treatment interventions and therefore, improving patient safety and reduction of associated cost to medical errors. This simulator provides a high value in 3D organ models due to its physical mechanical identical to the real ones are able to replicate the patient´s own organ and pathology. The main objective of MedicalPhant project is to develop and commercialized, based on MRI, ECO and CAT studies on patients, a cardiovascular personalized model of external and internal vasculature that allows simulating complex clinical situations due to cardiovascular diseases are the main cause of death globally. Currently, the simulator prototype has a technology level TRL6 and it has been validated in a relevant environment through its implementation in a real case study of cardiovascular surgery providing diagnostic capacity before intervention and patient´s safety after intervention. However, the company needs to work in the implementation of the business model, in the industrial adaptation of our prototype and, in achieving the certification of our 3D simulator to be commercialized. The key stakeholders involved in this project will be hospitals to carry out clinical trials, private, public hospitals and universities to use our technology, specialized organizations in charge of certificating our device to obtain the CE Mark and FDA, key opinion leaders to get a better penetration on the market and patient associations which will contribute to the dissemination of our innovative 3D printing technology in the cardiovascular market. The initial plan to commercialize the MedicalPhant consists in the combination of own production with a partner plus licensing of the technology. According to our estimation, the cumulative cash flow projected by VALIDA INNOVATION at year 5 will amount €10.3M meaning a ROI of 2.6%.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "MEDICALPHANT" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "MEDICALPHANT" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.;H2020-EU.2.3.;H2020-EU.2.1.)

BeatsDigTherapeutics (2019)

Project SCALE: Tailored Digital Therapeutics for Neurological and Brain Disorders

Read More  

Skye (2018)

Redefining Drone Safety and Autonomous Operation for Indoor Commercial Applications

Read More  

TPRPK (2018)

PpSC developing Topical Platelet-rich plasma Kit (TPRPK) in order to facilitate the further development, adoption and implement. of PRP for Healthcare with initial specialisation on cell rejuvenation

Read More